deltatrials
Completed PHASE1 INTERVENTIONAL NCT00083525

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Sponsor: Heidelberg Pharma AG

Conditions Advanced Malignancies
Interventions WX-UK1 in combination with Capecitabine
Updated 6 times since 2017 Last updated: Jan 21, 2008 Started: May 31, 2004
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00083525, this PHASE1 trial focuses on Advanced Malignancies and remains completed. Sponsored by Heidelberg Pharma AG, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotCompleted~Feb 2021 – ~Jul 2024 · 41 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Feb 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Heidelberg Pharma AG
  • United States Department of Defense
Data source: Heidelberg Pharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations